Skip to main content
IPHA
NASDAQ Life Sciences

Innate Pharma wraps up Phase 1 dose-escalation enrollment for IPH4502 ADC; early responses emerge in heavily pre-treated cancers

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.691
Mkt Cap
$162.02M
52W Low
$1.17
52W High
$2.63
52W Position info
45% above low
Off High info
36% below high
Rel. Volume
Market data snapshot near publication time

IPHA sits 45% above its 52-week low of $1.17.

Summary

Innate Pharma has completed enrollment in the Phase 1 dose escalation of its Nectin-4 ADC IPH4502, with early responses seen in heavily pre-treated solid tumors and a clean safety profile. The year-end data readout is a pivotal event for the cash-strapped biotech.


Key Events · Product Development and Regulatory · IPHA

  • Phase 1 Dose Escalation Enrollment Complete

    The IPH4502-101 study has enrolled 76 patients across France and the US, evaluating the Nectin-4 ADC in advanced solid tumors.

  • Early Efficacy Signals in Hard-to-Treat Cancers

    Objective responses have been observed in heavily pre-treated patients with post-enfortumab vedotin urothelial carcinoma, NSCLC, and HNSCC.

  • Favorable Safety Profile with Limited Hematologic Toxicity

    A proprietary linker appears to slow free exatecan release, minimizing bone marrow toxicity—a key differentiator from other ADCs.

  • Year-End 2026 Data Readout as Critical Catalyst

    Preliminary data from the full dose escalation cohort are expected by year-end, guiding dose optimization and next development steps.


Analysis · IPHA · Life Sciences

Enrollment is now complete in the dose-escalation portion of the Phase 1 study for IPH4502, a novel Nectin-4 ADC, with 76 patients on board. Early data reveal objective responses in heavily pre-treated patients with post-EV urothelial carcinoma, NSCLC, and HNSCC, alongside a favorable safety profile and limited hematological toxicity. For a company whose cash runway extends only into Q3 2026, this marks a critical de-risking event for its lead wholly-owned asset. Positive results could unlock partnership or financing interest, while the year-end data readout stands as a near-term catalyst that may determine whether the company can continue as a going concern.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IPHA was trading at $1.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $162M. The 52-week trading range was $1.17 to $2.63. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IPHA - Latest Insights

IPHA
Nov 18, 2026, 6:02 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.14
Real-time Price: $0.9499 info
Change: -$0.1901 (-17%) info
Market Cap: $121.089M info
IPHA
Nov 05, 2026, 6:20 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.46
Real-time Price: $0.9499 info
Change: -$0.5101 (-35%) info
Market Cap: $121.089M info
IPHA
Oct 27, 2026, 7:13 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.46
Real-time Price: $0.9499 info
Change: -$0.5101 (-35%) info
Market Cap: $121.089M info
IPHA
Sep 17, 2026, 6:30 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.93
Real-time Price: $0.9499 info
Change: -$0.9837 (-51%) info
Market Cap: $121.089M info
IPHA
Aug 19, 2026, 4:02 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.12
Real-time Price: $0.9499 info
Change: -$1.17 (-55%) info
Market Cap: $121.089M info